Gastroenterology Practice Questions

Q: What has contributed to the reduction of duodenal ulcer morbidity in the last decade?

Eradication of H. pylori. ### Eradication of H. pylori - The widespread success of **H. pylori eradication therapies** has directly addressed the primary cause of most duodenal ulcers [1]. - By eliminating the bacterial infection, the recurrence rate of ulcers dramatically decreases, leading to reduced morbidity [1]. *Use of proton pump inhibitors* - While **proton pump inhibitors (PPIs)** are highly effective in healing existing ulcers and managing symptoms, they do not address the underlying cause of *H. pylori* infection. - PPIs primarily reduce acid secretion but do not prevent the recurrence of ulcers driven by *H. pylori* [1]. *Lifestyle modifications* - **Lifestyle modifications** such as reducing stress, avoiding spicy foods, and quitting smoking can help manage symptoms and prevent exacerbations, but they are not primary treatments for duodenal ulcers. - These changes contribute to overall well-being but do not directly eliminate the main pathogenic factor, *H. pylori* [1]. *None of the options* - This option is incorrect because the **eradication of *H. pylori*** has demonstrably contributed to the reduction of duodenal ulcer morbidity in recent decades [1]. - The link between *H. pylori* and duodenal ulcers is well-established, and effective treatment for the infection has transformed ulcer management [1].

Q: Discriminant score is used for management of?

Alcoholic hepatitis. ***Alcoholic hepatitis*** - The **Maddrey Discriminant Function (MDF) score** is a widely used tool specifically for assessing the severity of alcoholic hepatitis [1]. - scores greater than or equal to 32 indicate **severe alcoholic hepatitis** and guide the decision for corticosteroid therapy. *Viral hepatitis* - Management of viral hepatitis (e.g., Hepatitis B or C) typically involves antiviral medications, and severity assessment relies on viral load, liver biopsy, and clinical features, not the **discriminant score**. - While liver function tests are important, specific discriminant scores are not the primary tool for guiding treatment decisions in **viral hepatitis**. *Variceal bleeding* - Prognostic scores for variceal bleeding include the **Child-Pugh score** and **MELD score**, which assess liver function and predict mortality in cirrhosis, but not the **discriminant score**. - Management focuses on endoscopic interventions and medications to prevent re-bleeding, not on a discriminant score. *Weight loss* - Weight loss is a symptom, not a diagnosis requiring a specific discriminant score for management. - Its management involves identifying and addressing the **underlying cause**, which can be diverse and does not typically involve such a score.

Q: Which of the following is the site of venous thrombosis in Budd-Chiari syndrome?

Hepatic vein. ***Hepatic vein*** - **Budd-Chiari syndrome** is specifically defined by **thrombosis of the hepatic veins** [3] or the suprahepatic inferior vena cava, obstructing venous outflow from the liver. - This obstruction leads to **hepatic congestion** [2], liver enlargement, abdominal pain, and ascites. *Infrahepatic inferior vena cava* - While thrombosis can occur in the inferior vena cava, if it is located **below the liver**, it would not directly cause the classic features of Budd-Chiari syndrome. - Obstruction at this level would primarily lead to **lower extremity edema** and potentially renal vein thrombosis. *Infrarenal inferior vena cava* - Thrombosis in the **infrarenal portion of the IVC** would cause symptoms in the lower body, such as leg swelling [3], but not the hepatic congestion characteristic of Budd-Chiari syndrome. - This condition is distinct and typically presents with symptoms localized to the **inferior vena cava drainage area below the kidneys**. *Portal vein* - **Portal vein thrombosis** causes **portal hypertension** but does not directly involve the hepatic veins [1]. - While it can lead to ascites, it does not typically cause the acute, severe hepatic necrosis and sinusoidal congestion seen in Budd-Chiari syndrome as liver outflow is not obstructed.

Q: Most effective medication in Gastroesophageal Reflux Disease (GERD) is:

PPI. ***PPI*** - **Proton pump inhibitors (PPIs)** are considered the most effective medications for GERD because they **irreversibly block the H+/K+-ATPase pump** in gastric parietal cells, leading to substantial and prolonged reduction in acid secretion. [1] - This profound acid suppression promotes **healing of esophageal erosions** and provides superior symptom relief compared to other drug classes. [1] *Antacids* - **Antacids** neutralize existing stomach acid, providing **rapid but temporary symptomatic relief**. [1] - They do not inhibit acid production and are **ineffective for long-term management** or healing of esophageal damage in GERD. *Prokinetic drugs* - **Prokinetic agents** enhance esophageal motility and gastric emptying, which can be beneficial in some GERD patients by reducing acid exposure. - However, they do **not reduce acid secretion** and are generally less effective than PPIs for primary GERD treatment. *H2 blockers* - **H2-receptor antagonists (H2 blockers)** reduce stomach acid production by blocking histamine H2 receptors on parietal cells, leading to a moderate decrease in acid secretion. - While effective for mild GERD, they are generally **less potent and provide less sustained acid suppression** than PPIs [1], and patients can develop **tachyphylaxis** (tolerance) to their effects.

Q: Which of the following is not typically used in the management of pneumatosis cystoides intestinalis?

Albendazole. ***Albendazole*** - **Albendazole** is an **anti-parasitic medication** used to treat helminthic infections [2]. - While parasitic infections can sometimes cause gastrointestinal symptoms, it is not a standard treatment for **pneumatosis cystoides intestinalis**, which primarily involves gas cysts in the bowel wall. *High flow oxygen* - **High flow oxygen** is a common and effective treatment for pneumatosis cystoides intestinalis. - It works by increasing the partial pressure of nitrogen in the blood, creating a **diffusion gradient** that promotes the absorption of nitrogen gas from the cysts in the bowel wall. *Metronidazole* - **Metronidazole** is an antibiotic that is often used in the management of pneumatosis cystoides intestinalis, especially when bacterial overgrowth or infection is suspected. - It can help to reduce gas production by **anaerobic bacteria** in the gut, which may contribute to the formation of gas cysts. *Sulfasalazine* - **Sulfasalazine** is an anti-inflammatory drug used in the treatment of inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease [1]. - In cases where pneumatosis cystoides intestinalis is secondary to an **inflammatory bowel condition**, sulfasalazine may be used to address the underlying inflammation that might be contributing to the gas cysts [1].

Q: Most common presentation of Peutz-Jeghers syndrome is

Intussusception due to hamartomatous polyps. ***Intussusception due to hamartomatous polyps*** - **Intussusception** is a common and often the first clinical manifestation of Peutz-Jeghers syndrome, caused by the characteristic **hamartomatous polyps** acting as a lead point [1]. - These polyps, particularly in the small intestine, can prolapse into an adjacent segment of the bowel, leading to bowel obstruction and pain [1]. *Increased risk of pancreatic cancer* - While patients with Peutz-Jeghers syndrome do have an **increased risk of various cancers**, including pancreatic cancer, this is not the most common initial presentation [2]. - Cancer development typically occurs later in life, whereas intussusception can occur in childhood or early adulthood. *Increased risk of melanoma* - Peutz-Jeghers syndrome is primarily associated with an increased risk of gastrointestinal and other visceral cancers, not typically with an **increased risk of melanoma**. - The distinctive **mucocutaneous pigmentation** seen in PJS can be mistaken for other pigmented lesions, but it is not indicative of melanoma risk. *Bowel malabsorption issues* - Although the polyps can sometimes cause bleeding or abdominal pain, **significant malabsorption** is not a characteristic or common direct presentation of Peutz-Jeghers syndrome. - Malabsorption might be a secondary complication in severe, rare cases following extensive resections or severe chronic inflammation, but not a primary presentation.

Q: The drug used in steroid-refractory acute severe ulcerative colitis is:

Infliximab. ***Infliximab*** - **Infliximab**, an **anti-TNF-α monoclonal antibody**, is the preferred first-line rescue therapy for **steroid-refractory acute severe ulcerative colitis** according to current **ECCO/ACG/BSG guidelines**. - It offers dual benefits of **acute rescue** and **long-term maintenance therapy**, with superior outcomes compared to cyclosporine as demonstrated in the **CONSTRUCT trial**. *Steroids* - The question specifically mentions "**steroid-refractory**" disease, indicating the patient has already failed to respond to **corticosteroid therapy**. - Using steroids again would be inappropriate as the patient has already demonstrated **resistance** to this treatment modality. *Cyclosporine* - **Cyclosporine** is an alternative **calcineurin inhibitor** used as rescue therapy when **infliximab is contraindicated** or unavailable. - It has a **rapid onset** but requires **bridge therapy** to maintenance agents and has more **nephrotoxicity** and **drug interactions** compared to infliximab. *Sulfasalazine* - **Sulfasalazine** is an **aminosalicylate** used for **mild to moderate** ulcerative colitis and maintenance of remission. - It lacks the **potent immunosuppressive** effects required for **acute severe, steroid-refractory** disease and would be insufficient in this clinical scenario.

Q: Which condition is associated with the highest risk of colorectal cancer?

Familial polyposis. ***Familial polyposis*** - Familial polyposis, particularly **Familial Adenomatous Polyposis (FAP)**, is associated with a nearly **100% risk of colorectal cancer** if untreated due to the development of numerous adenomatous polyps [1]. - Patients with FAP typically require **prophylactic colectomy** due to this high risk [1]. *Crohn's disease* - While Crohn's disease does increase the risk of colorectal cancer, the risk is **lower** compared to conditions like familial polyposis. - Colorectal cancer develops more commonly in long-standing cases and with **persistence of inflammation**. *Ulcerative colitis* - Ulcerative colitis also carries an increased risk for colorectal cancer, but it requires a longer duration of disease (often **over 8 years**) to significantly increase risk. - Cancer risk in ulcerative colitis is related to the extent of **colonic involvement**, making it less severe than familial polyposis. *Infantile polyp* - Infantile polyps are benign growths occurring in children and are generally **not associated with increased colorectal cancer risk** [1]. - These polyps usually **do not progress** to malignancy and are often discovered incidentally.

Question 1

What has contributed to the reduction of duodenal ulcer morbidity in the last decade?

Accepted Answer

Eradication of H. pylori

Answer

Use of proton pump inhibitors

Answer

Lifestyle modifications

Answer

None of the options

Question 2

Discriminant score is used for management of?

Accepted Answer

Alcoholic hepatitis

Answer

Viral hepatitis

Answer

Variceal bleeding

Answer

Weight loss

Question 3

In a young, otherwise healthy patient with a newly suspected diagnosis of peptic ulcer disease, what would be the most appropriate course of action in the emergency department?

Accepted Answer

Begin symptomatic and therapeutic treatment with a proton pump inhibitor (e.g., omeprazole)

Answer

Immediate referral for endoscopy

Answer

Begin combination therapy with an H2 receptor antagonist, proton pump inhibitor, and antacids

Answer

Begin empiric treatment of H. pylori with a triple antibiotic regimen after confirmation of infection

Question 4

A 40-year-old woman with Crohn's disease reports multiple bowel movements with frequent stools. She was previously treated with a mesalamine derivative "Pentasa" and in the latest episode of the disease flare-up, she didn't tolerate the oral steroid therapy with budesonide. What is the next appropriate step in her treatment?

Accepted Answer

Azathioprine

Answer

Sulfasalazine

Answer

Prednisolone (oral)

Answer

Hydrocortisone (IV)

Question 5

Which of the following is the site of venous thrombosis in Budd-Chiari syndrome?

Accepted Answer

Hepatic vein

Answer

Infrahepatic inferior vena cava

Answer

Infrarenal inferior vena cava

Answer

Portal vein

Question 6

Most effective medication in Gastroesophageal Reflux Disease (GERD) is:

Accepted Answer

PPI

Answer

Antacids

Answer

Prokinetic drugs

Answer

H2 blockers

Question 7

Which of the following is not typically used in the management of pneumatosis cystoides intestinalis?

Accepted Answer

Albendazole

Answer

Sulfasalazine

Answer

Metronidazole

Answer

High flow oxygen

Question 8

Most common presentation of Peutz-Jeghers syndrome is

Accepted Answer

Intussusception due to hamartomatous polyps

Answer

Increased risk of pancreatic cancer

Answer

Increased risk of melanoma

Answer

Bowel malabsorption issues

Question 9

The drug used in steroid-refractory acute severe ulcerative colitis is:

Accepted Answer

Infliximab

Answer

Steroids

Answer

Cyclosporine

Answer

Sulfasalazine

Question 10

Which condition is associated with the highest risk of colorectal cancer?

Accepted Answer

Familial polyposis

Answer

Crohn's disease

Answer

Ulcerative colitis

Answer

Infantile polyp

Gastroenterology — MCQs

Gastroenterology — MCQs

On this page

Practice by Chapter

Want unlimited practice?